Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Public ClinicalTrials.gov record NCT00748709. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.
Study identification
- NCT ID
- NCT00748709
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2008 (Actual)
- Primary completion
- Nov 1, 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Feb 11, 2025
Started 2008
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1200.26.3 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1200.26.11 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1200.26.9 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 1200.26.1 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1200.26.13 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 1200.26.4 Boehringer Ingelheim Investigational Site | Albany | New York | — | — |
| 1200.26.2 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1200.26.7 Boehringer Ingelheim Investigational Site | Kettering | Ohio | — | — |
| 1200.26.12 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1200.26.8 Boehringer Ingelheim Investigational Site | Tyler | Texas | — | — |
| 1200.26.6 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 1200.26.10 Boehringer Ingelheim Investigational Site | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00748709, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2025 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00748709 live on ClinicalTrials.gov.